Evidence map›Paper›PMID 27648366›Full record

ArticleAmerican journal of cancer research2016

Prognostic significance of MST1R dysregulation in renal cell tumors.

Ana S Pires-Luís, Márcia Vieira-Coimbra, Maria João Ferreira, João Ramalho-Carvalho, Pedro Costa-Pinheiro, Luís Antunes, Paula C Dias, Francisco Lobo, Jorge Oliveira, Inês Graça and 2 more

Abstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ana S Pires-LuísCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology - Portuguese Oncology Institute of PortoPorto, Portugal.
Márcia Vieira-CoimbraCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology - Portuguese Oncology Institute of PortoPorto, Portugal.
Maria João FerreiraCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of Porto Porto, Portugal.
João Ramalho-CarvalhoCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of Porto Porto, Portugal.
Pedro Costa-PinheiroCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of Porto Porto, Portugal.
Luís AntunesDepartment of Epidemiology - Portuguese Oncology Institute of Porto Porto, Portugal.
Paula C DiasDepartment of Pathology - Portuguese Oncology Institute of Porto Porto, Portugal.
Francisco LoboDepartment of Urology - Portuguese Oncology Institute of Porto Porto, Portugal.
Jorge OliveiraDepartment of Urology - Portuguese Oncology Institute of Porto Porto, Portugal.
Inês GraçaCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of Porto Porto, Portugal.
Rui HenriqueCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology - Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of PortoPorto, Portugal.
Carmen JerónimoCancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of PortoPorto, Portugal.
Universidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage stimulating 1 receptor (MST1R) is a C-MET proto-oncogene family receptor tyrosine kinase. Promoter methylation patterns determine transcription of MST1R variants as hypermethylation of a region upstream of transcription start site (TSS) is associated with lack of MST1R long transcript (MST1R long) and expression of a short transcript with oncogenic potential. Thus, we aimed to investigate MST1R variant transcript regulation in renal cell tumors (RCT) and assess their prognostic potential. We found, in a series of 120 RCT comprising the four main subtypes (clear cell, papillary and chromophobe renal cell carcinoma, and oncocytoma), that higher methylation levels close to TSS were associated with total MST1R expression levels (MST1R total) in primary tumors (p=0.049) and renal cancer cell lines. After demethylating treatment, MST1R long/MST1R total ratio increased, as expected, in two renal cell carcinoma cell lines tested. However, in primary tumors with hypermethylation upstream of TSS, a decrease in MST1R long/MST1R total ratio was not detected, although higher expression ratio of nuclear factor-κB was apparent. Furthermore, survival analysis demonstrated that MST1R long/MST1R total ratio was independently associated with shorter disease-specific and disease-free survival, whereas MST1R total expression associated with shorter disease-specific survival. In conclusion, although promoter methylation patterns seem to determine MST1R global transcription regulation in renal cell carcinoma, other mechanisms might contribute to deregulate MST1R variant expression in RCT. Nevertheless, MST1R total expression and MST1R long/MST1R total ratio modulate the biological and clinical aggressiveness of renal cell carcinoma, as depicted by its prognostic significance, a finding that requires validation in a larger independent series.

Indexed as

epigeneticsMST1RMST1R expressionMST1R promoter methylationRenal cell tumorsRON

Identifiers

PMID27648366
PMCPMC5004080
OpenAlexW2530278462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.